Elicio Therapeutics, Inc. (ELTX) Free cash flow 2020–2025
Elicio Therapeutics, Inc. (ELTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$37.0MFY2025 · since FY2020: -$22.9M → -$37.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$37.0M | +0.5% |
| FY2024 | -$37.2M | -13.4% |
| FY2023 | -$32.8M | -43.5% |
| FY2022 | -$22.8M | +56.9% |
| FY2021 | -$53.0M | -131.3% |
| FY2020 | -$22.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTX financial trends
ELTX RevenueELTX Net incomeELTX Net marginELTX Gross profitELTX Gross marginELTX Operating incomeELTX Operating marginELTX Operating cash flowELTX Capital expendituresELTX Return on equityELTX Stock buybacksELTX Dividends paidELTX Total assetsELTX Total liabilitiesELTX Shareholders’ equityELTX overview →